Replies to post #146936 on Biotech Values

[turtlepower]

Those without much oncology experiences won't develop the drug to its potential. Look at ARRY MEK Selumetinib licensed to AZN. The drug is active, but still in ph2 after 8 years. Similarly active MEK inhibitor GSK licensed just 3 years ago already filed NDA in BRAF melanoma, and in ph3 combination with BRAF inhibitor for BRAF melanoma leaping in front of even Roche who has the first drug approved for BRAF melanoma.

I believe Genentech licensed TDM1 way back in 2000 and started the first P3 in 2009, 9 years after. That appears to be similar progress to AZN which licensed Selumetinib in 2003 and a P3 will be launched this year.

So about GSK, my point exactly. GSK doesn't have any of the top 10 best selling oncology drugs but they have unlimited resources and they're ahead of Roche, a company that CLDX shareholders appear to prefer.